Navigation Links
Watson's Generic ARTHROTEC(R) Receives FDA Approval
Date:7/11/2012

PARSIPPANY, N.J., July 11, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc - Florida has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium and Misoprostol Delayed-Release Tablets, the generic equivalent to G.D. Searle's ARTHROTEC®. Watson plans to launch the product in the fourth quarter of 2012.

For the twelve months ending May 31, 2012, ARTHROTEC® had total U.S. sales of approximately $130 million according to IMS Health data. ARTHROTEC® is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and Watson's Annual Report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

ARTHROTEC® is a registered trademark of G.D. Searle LLC, a subsidiary of Pfizer Inc.CONTACTS:

Investors: Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

 


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
2. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
3. Wockhardt honoured with 2012 DIANA Award for Best Overall Generic Manufacturer
4. NABP Applies for New .PHARMACY Generic Top-Level Domain to Provide a Secure Destination for Consumers
5. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
6. Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
7. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
8. Mylan Launches Generic Version of Lipitor®
9. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
10. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
11. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
Breaking Medicine Technology:
(Date:2/5/2016)... Lake City, UT (PRWEB) , ... February 05, 2016 , ... ... Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist ... Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... the election of Patrick McDermott as Chairman of the National Board of Directors. Mr. ... as Chairman of the Board,” stated Leslie A. Chambers , APDA President and ...
Breaking Medicine News(10 mins):